Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript
Bausch + Lomb (BLCO) reported Q3 2026 earnings with 8% revenue growth to $1.375B, 34% adjusted EBITDA increase, and 23.6% margin. All segments grew: Pharmaceuticals +11%, Surgical +9%, Vision Care +6%. The company reduced net leverage to 4.1x and remains confident in meeting its 3-year plan targets.
How this was made
The 30-second read
Why it matters
The disclosed growth metrics and margin expansion suggest BLCO is on track with its 3‑year plan, likely supporting a positive price move.
Market read
First‑time disclosure of Q3 2026 earnings with strong growth, providing fresh data for traders.
What to watch
Potential headwinds from foreign‑exchange impacts and upcoming competitive product launches could temper upside.
Background
The transcript provides the company's own commentary on Q3 performance and strategic priorities.
Ticker impact
Q3 2026 earnings call disclosed 8% constant‑currency revenue growth, 34% adjusted EBITDA increase and 23.6% EBITDA margin, with segment growth across pharmaceuticals, surgical and vision care.
likely upside as market prices in robust revenue and margin expansion
The company beat prior guidance on both top‑line and profitability, and the commentary highlights continued momentum across all segments.
Market effects
Eye‑care and medical device sector may see broader optimism from BLCO's strong performance.
U.S. healthcare stocks could benefit from the upbeat earnings.
Reinforces confidence in global ophthalmic and surgical equipment demand.
Counterpoint
If the market had already priced in strong growth, the earnings may be a relief rally rather than a breakout.
Key entities
- CompanyBausch + Lomb
Eye‑care and medical device manufacturer reporting Q3 2026 results.
- ExecutiveOsama A. Eldessouky
Presented detailed financial results during the earnings call.
